Biotech

Johnson & Johnson (NYSE:JNJ) on Thursday presented detailed results from its Phase 2/3 ENERGY study showing that IMAAVY (nipocalimab-aahu) achieved a statistically significant, durable hemoglobin response in patients with warm autoimmune hemolytic anemia (wAIHA). The rare blood disorder occurs...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported new clinical data showing that CASGEVY (exagamglogene autotemcel) delivered efficacy and safety outcomes in children ages 5 to 11 with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT) The data were consistent...

Harrow Inc. (NASDAQ:HROW) on Wednesday announced the relaunch of VERKAZIA (cyclosporine ophthalmic emulsion) 0.1%, a prescription treatment for vernal keratoconjunctivitis (VKC), a serious allergic eye condition that primarily affects children. The eye care company said the move reflects its...

Humacyte Inc. (NASDAQ:HUMA) stock plunged Thursday despite reporting positive interim Phase 3 data for its acellular tissue-engineered vessel (ATEV), as investors focused on a heavily dilutive stock offering announced alongside the clinical update. On Wednesday, Humacyte released interim Phase 3...

Novartis AG (NYSE:NVS) said Thursday that the biomarker cohort of its Phase 1/2 FORTITUDE study evaluating investigational therapy del-brax met both its primary and key secondary endpoints in patients with facioscapulohumeral muscular dystrophy (FSHD), a rare neuromuscular disease. Trial Meets...

Sanofi SA (NASDAQ:SNY) on Wednesday announced that it will discontinue its Phase 3 MOBILIZE study evaluating riliprubart in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who had not responded to standard treatments. CIDP is a rare, acquired autoimmune disorder of the...